Exosomes in Cancer: Circulating Immune-Related Biomarkers

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2020 Jan 10

PMID 31915681

Citations 29

Authors

Alicja Gluszko

Miroslaw J Szczepanski

Nils Ludwig

Shafaq M Mirza

Wioletta Olejarz

Affiliations

Soon will be listed here.

Abstract

Exosomes, the smallest vesicles (30-100 nm) among multivesicular bodies, are released by all body cells including tumor cells. The cargo they transfer plays an important role in intercellular communication. Tumor-derived exosomes (TEXs) maintain interactions between cancer cells and the microenvironment. Emerging evidence suggests that tumor cells release a large number of exosomes, which may not only influence proximal tumor cells and stromal cells in the local microenvironment but can also exert systemic effects as they are circulating in the blood. TEXs have been shown to boost tumor growth promote progression and metastatic spread via suppression or modification of the immune response towards cancer cells, regulation of tumor neo-angiogenesis, pre-metastatic niche formation, and therapy resistance. In addition, recent studies in patients with cancer suggest that TEXs could serve as tumor biomarker reflecting partially the genetic and molecular content of the parent cancer cell (i.e., as a so-called "liquid biopsy"). Furthermore, recent studies have demonstrated that exosomes may have immunotherapeutic applications, or can act as a drug delivery system for targeted therapies with drugs and biomolecules.

Citing Articles

Exosomal miRNAs involvement in pathogenesis, diagnosis, and treatment of rheumatoid arthritis.

Sadeghi M, Tavakol Afshari J, Fadaee A, Dashti M, Kheradmand F, Dehnavi S Heliyon. 2025; 11(2):e41983.

PMID: 39897907 PMC: 11786886. DOI: 10.1016/j.heliyon.2025.e41983.

A novel tumor-derived exosomal gene signature predicts prognosis in patients with pancreatic cancer.

Wang Y, Liang C, Liu X, Cheng S Transl Cancer Res. 2024; 13(8):4324-4340.

PMID: 39262474 PMC: 11384923. DOI: 10.21037/tcr-23-2354.

Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies.

Olejarz W, Sadowski K, Szulczyk D, Basak G Int J Mol Sci. 2024; 25(14).

PMID: 39062986 PMC: 11276786. DOI: 10.3390/ijms25147743.

Engineered exosomes and composite biomaterials for tissue regeneration.

Hu W, Wang W, Chen Z, Chen Y, Wang Z Theranostics. 2024; 14(5):2099-2126.

PMID: 38505616 PMC: 10945329. DOI: 10.7150/thno.93088.

Emerging role of exosome-derived non-coding RNAs in tumor-associated angiogenesis of tumor microenvironment.

Duan S, Fu W, Jiang Y, Peng L, Ousmane D, Zhang Z Front Mol Biosci. 2023; 10:1220193.

PMID: 37602326 PMC: 10436220. DOI: 10.3389/fmolb.2023.1220193.

References

Thery C, Ostrowski M, Segura E . Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009; 9(8):581-93. DOI: 10.1038/nri2567. View

Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki J . Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014; 124(25):3748-57. PMC: 4263983. DOI: 10.1182/blood-2014-05-576116. View

Szajnik M, Czystowska M, Szczepanski M, Mandapathil M, Whiteside T . Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One. 2010; 5(7):e11469. PMC: 2908536. DOI: 10.1371/journal.pone.0011469. View

Kim Y, Ahn J, Kim S, Kim H, Kim S, Kang J . The potential theragnostic (diagnostic+therapeutic) application of exosomes in diverse biomedical fields. Korean J Physiol Pharmacol. 2018; 22(2):113-125. PMC: 5840070. DOI: 10.4196/kjpp.2018.22.2.113. View

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

Wubbolts R, Leckie R, Veenhuizen P, Schwarzmann G, Mobius W, Hoernschemeyer J . Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem. 2003; 278(13):10963-72. DOI: 10.1074/jbc.M207550200. View

Wang Y, Lee C . MicroRNA and cancer--focus on apoptosis. J Cell Mol Med. 2009; 13(1):12-23. PMC: 3823033. DOI: 10.1111/j.1582-4934.2008.00510.x. View

Robbins P, Morelli A . Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014; 14(3):195-208. PMC: 4350779. DOI: 10.1038/nri3622. View

Ostrowski M, Carmo N, Krumeich S, Fanget I, Raposo G, Savina A . Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2009; 12(1):19-30. DOI: 10.1038/ncb2000. View

10.

Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L . Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007; 67(7):2912-5. DOI: 10.1158/0008-5472.CAN-07-0520. View

11.

Dolo V, DAscenzo S, Violini S, Pompucci L, Festuccia C, Ginestra A . Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis. 1999; 17(2):131-40. DOI: 10.1023/a:1006500406240. View

12.

Andre F, Schartz N, Movassagh M, Flament C, Pautier P, Morice P . Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002; 360(9329):295-305. DOI: 10.1016/S0140-6736(02)09552-1. View

13.

Zhang B, Pan X, Cobb G, Anderson T . microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006; 302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.028. View

14.

Peterson M, Otoc N, Sethi J, Gupta A, Antes T . Integrated systems for exosome investigation. Methods. 2015; 87:31-45. DOI: 10.1016/j.ymeth.2015.04.015. View

15.

Wesolowska A, Piwocka K . [Exosomal microRNAs as a part of the cell-cell communication in cancer]. Postepy Biochem. 2017; 63(2):110-118. View

16.

Welton J, Khanna S, Giles P, Brennan P, Brewis I, Staffurth J . Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics. 2010; 9(6):1324-38. PMC: 2877990. DOI: 10.1074/mcp.M000063-MCP201. View

17.

Escudier B, Dorval T, Chaput N, Andre F, Caby M, Novault S . Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005; 3(1):10. PMC: 554765. DOI: 10.1186/1479-5876-3-10. View

18.

Morse M, Garst J, Osada T, Khan S, Hobeika A, Clay T . A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005; 3(1):9. PMC: 551593. DOI: 10.1186/1479-5876-3-9. View

19.

Boing A, Hau C, Sturk A, Nieuwland R . Platelet microparticles contain active caspase 3. Platelets. 2008; 19(2):96-103. DOI: 10.1080/09537100701777295. View

20.

Cocucci E, Racchetti G, Meldolesi J . Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009; 19(2):43-51. DOI: 10.1016/j.tcb.2008.11.003. View